Zydus Cadila receives tentative approval from USFDA for Cariprazine Capsules

Zydus Cadila's U.S. subsidiary Zydus Pharmaceuticals (USA) Inc. has received tentative approval from the USFDA to market Cariprazine Capsules in the strengths of 1.5 mg, 3 mg and 4.5 mg, and 6 mg (US RLD: VRAYLAR® ). Cariprazine is an atypical antipsychotic. Zydus' Cariprazine Capsules are indicated for the treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar disorder. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 325 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 467.55 as compared to the previous close of Rs. 462.65. The total number of shares traded during the day was 104720 in over 3059 trades.

The stock hit an intraday high of Rs. 471.00 and intraday low of 461.75. The net turnover during the day was Rs. 48953094.00.

Source : Equity Bulls

Keywords

CadilaHealthcare INE010B01027 CADILAHC USFDA TentativeApproval ZydusPharmaceuticals Cariprazine